These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2294105)

  • 41. A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III.
    Naski MC; Shafer JA
    J Biol Chem; 1991 Jul; 266(20):13003-10. PubMed ID: 2071587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides.
    Hanna LS; Scheraga HA; Francis CW; Marder VJ
    Biochemistry; 1984 Sep; 23(20):4681-7. PubMed ID: 6238619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow.
    Zhu S; Chen J; Diamond SL
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1528-1536. PubMed ID: 29724819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
    Slaughter TF; LeBleu TH; Douglas JM; Leslie JB; Parker JK; Greenberg CS
    Anesthesiology; 1994 Mar; 80(3):520-6. PubMed ID: 8141448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.
    Becker DL; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A two-step fibrinogen--fibrin transition in blood coagulation.
    Blombäck B; Hessel B; Hogg D; Therkildsen L
    Nature; 1978 Oct; 275(5680):501-5. PubMed ID: 692730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural examination of the influence of phosphorylation on the binding of fibrinopeptide A to bovine thrombin.
    Maurer MC; Peng JL; An SS; Trosset JY; Henschen-Edman A; Scheraga HA
    Biochemistry; 1998 Apr; 37(17):5888-902. PubMed ID: 9558322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of thrombin and fibrinogen and the polymerization of fibrin monomer.
    Scheraga HA
    Ann N Y Acad Sci; 1983 Jun; 408():330-43. PubMed ID: 6575693
    [No Abstract]   [Full Text] [Related]  

  • 52. High-resolution NMR studies of fibrinogen-like peptides in solution: interaction of thrombin with residues 1-23 of the A alpha chain of human fibrinogen.
    Ni F; Konishi Y; Frazier RB; Scheraga HA; Lord ST
    Biochemistry; 1989 Apr; 28(7):3082-94. PubMed ID: 2742826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen.
    Naski MC; Fenton JW; Maraganore JM; Olson ST; Shafer JA
    J Biol Chem; 1990 Aug; 265(23):13484-9. PubMed ID: 2380171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombin specificity with tripeptide chromogenic substrates: comparison of human and bovine thrombins with and without fibrinogen clotting activities.
    Sonder SA; Fenton JW
    Clin Chem; 1986 Jun; 32(6):934-7. PubMed ID: 3708816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural basis for sequential cleavage of fibrinopeptides upon fibrin assembly.
    Pechik I; Yakovlev S; Mosesson MW; Gilliland GL; Medved L
    Biochemistry; 2006 Mar; 45(11):3588-97. PubMed ID: 16533041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
    Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
    J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of fibrin polymers on thrombin-catalyzed plasma factor XIIIa formation.
    Greenberg CS; Miraglia CC
    Blood; 1985 Aug; 66(2):466-9. PubMed ID: 2861869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
    Rooney MM; Mullin JL; Lord ST
    Biochemistry; 1998 Sep; 37(39):13704-9. PubMed ID: 9753458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Properties of 2 fibrin monomer species which differ in the degree of thrombin activation. Characteristics of successively appearing active sites].
    Lugovskoĭ EV; Gogolinskaia GK; Derzskaia SG; Belitser VA
    Biokhimiia; 1978 Jun; 43(6):1045-53. PubMed ID: 667211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fibrinopeptides A and B release in the process of surface fibrin formation.
    Riedel T; Suttnar J; Brynda E; Houska M; Medved L; Dyr JE
    Blood; 2011 Feb; 117(5):1700-6. PubMed ID: 21106983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.